Lpath Completes Enrollment of Patients in iSONEP(TM) Phase 1 Clinical Trial

SAN DIEGO, CA--(Marketwire - August 18, 2009) - Lpath, Inc. (OTCBB: LPTN), the category
leader in lipidomics-based therapeutics, has completed the enrollment and
dosing of 15 wet AMD patients in a multi-center, open label, single-arm
Phase 1 study of iSONEP administered as a single intravitreal injection to
the study eye.

The drug was well tolerated in all 15 patients, and there were no
drug-related serious adverse events reported at any of the five dose levels
(0.2 mg/eye to 1.8 mg/eye).

In addition, several patients showed a reduction in retinal thickness and
regression of lesion size, the two primary efficacy-related endpoints in a
single-dose Phase 1 trial. All of these patients had received prior
treatments that included at least two doses of Lucentis® and/or
Avastin®, the two leading treatment options for wet AMD patients, but
were not responding well to these treatments, implying that their lesions
were challenging from a treatment perspective.

The company is expected to release a complete analysis of efficacy when all
the data is available later this quarter.

Scott Pancoast, Lpath's president and chief executive officer, stated, "The
excellent safety record from our Phase 1 study, combined with the efficacy
signal from several of the patients, warrants further investigation of the
safety and efficacy of iSONEP in one or more Phase 2 trials."

About Lpath

San Diego-based Lpath, Inc. is the category leader in lipidomics-based
therapeutics, an emerging field of medicine that targets bioactive
signaling lipids for treating a wide range of human disease. Lpath's
ImmuneY2T drug-discovery engine has the unique ability to generate
therapeutic antibodies that bind to and inhibit bioactive lipids that
contribute to disease. The company is currently advancing three drug
candidates, two of which -- ASONEPT for cancer and iSONEPT for AMD --
are in late-Phase 1 clinical trials. For ASONEP, Lpath has joined with
international drug giant Merck-Serono under a worldwide exclusive license
and development partnership. For more information, go to www.Lpath.com.

Trademarks are the property of their respective owners.